MPI Research has always set itself apart from other preclinical laboratories by offering sponsors fast starting, high quality, preclinical research at competitive prices. The expansion projects currently in progress, ultimately adding 100 new animal rooms by the end of 2005. These expansions will insure sponsors the timely study starts they’ve come to expect from MPI Research. However, without an accurate, on time report, there is no value in a fast study start. The staff at MPI Research is dedicated to helping sponsors meet and exceed their timeline requirements. MPI Research is again proud to announce another industry leading, record setting year for on time reporting.

For the period of 2003-2004, MPI Research has mailed nearly 2,352 study reports with an overall on time percentage of 98%. Over that two-year period, 86.5% of the reports mailed were mailed earlier than the timelines promised to sponsors, inclusive of expedited reports. In 2004, over 90% of all reports have been mailed to sponsors early, a further improvement on the stellar performance of 2003. This incredible early reporting achievement is even more remarkable considering MPI Research standard reporting schedules meet or exceed all toxicology industry standards.

Mary Ann Scott, Director of Regulatory Affairs, commented, “We are extremely proud of our record of on-time and early reporting and are committed to continuous improvements to maintain this high level of performance. The implementation of completely electronic data capture over the last several years, including a recent upgrade to Provantis 6.5 and the just completed validation of MPIRS (MPI proprietary reporting software), makes MPI a forerunner in validated data collection and reporting systems. These efforts will enable MPI Research to continue the level of performance our sponsors have come to expect. The MPI Regulatory Affairs team is a key participant in the FDA sponsored Standards for Exchange of Preclinical Data (SEND) Consortium to expand the use of electronic files in the reporting and submission of preclinical study results. We also invite attendees of the 2005 Society of Toxicology meeting in New Orleans to attend the SEND reception on Monday, March 7, 2005, from 5-7pm at the Hilton Riverside Hotel. Representatives from industry and the FDA will give insider perspectives on the SEND process and goals. MPI Research is proud to help sponsor this forum on such an important initiative.”

MPI Research exists to provide comprehensive non-clinical research that meets the requirements of pharmaceutical, medical device, animal health and chemical companies as well as governmental agencies as we partner together to bring safer, healthier products to the world. MPI Research employees specialize in a wide variety of scientific disciplines including toxicology, pharmacology, metabolism, pathology, clinical pathology, reproductive and developmental biology, veterinary science, neuroscience, experimental therapeutics, immunotoxicology, analytical chemistry, computer science, regulatory science, and statistics.

Home | News